Skip Navigation


JAC Advance Access originally published online on July 28, 2004
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
54/3/582    most recent
dkh396v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (12)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Springer, K. L.
Right arrow Articles by Weinberg, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Springer, K. L.
Right arrow Articles by Weinberg, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy 2004 54(3):582-586; doi:10.1093/jac/dkh396
JAC vol.54 no.3 © The British Society for Antimicrobial Chemotherapy 2004; all rights reserved.

Leading article

Cytomegalovirus infection in the era of HAART: fewer reactivations and more immunity

Kathryn L. Springer1 and Adriana Weinberg1,2,*

Departments of 1 Medicine and 2 Pediatrics, University of Colorado School of Medicine, Denver, Colorado, USA

* Correspondence address. UCHSC, 4200 E 9th Ave., Denver, CO 80262, USA. Tel: +1-303-315-4624; Fax: +1-303-315-1787; Email: adrianna.weinberg{at}uchsc.edu

The incidence of cytomegalovirus (CMV) disease, once the most common and highly feared viral complication of AIDS, has dramatically decreased with the advent of highly active antiretroviral therapy (HAART). HAART-associated changes in the epidemiology of CMV disease resulted from the increase in CMV-specific immune responses coupled with the decrease in CMV reactivation. However, CMV disease continues to afflict HIV-infected patients on HAART when CD4+ cell counts fail to rise above 100 cells/mm3 and when reconstitution of normal CMV-specific immune responses does not occur. The latter scenario may lead to recurrent or de novo CMV end-organ disease, or to the recently described CMV immune recovery vitritis. HAART-associated immune reconstitution offers unique opportunities to investigate the virological and immunological correlates of protection against CMV disease. Although the full extent of CMV-specific immune reconstitution has not been defined thus far, CMV-specific interferon-{gamma} production has been shown to be significantly associated with protection against CMV reactivation and recurrent disease.

Keywords: HIV , immune reconstitution , AIDS , opportunistic infections


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Rheumatology (Oxford)Home page
B. Kahaleh
The microvascular endothelium in scleroderma
Rheumatology, October 1, 2008; 47(suppl_5): v14 - v15.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
B. J. Ryckman, B. L. Rainish, M. C. Chase, J. A. Borton, J. A. Nelson, M. A. Jarvis, and D. C. Johnson
Characterization of the Human Cytomegalovirus gH/gL/UL128-131 Complex That Mediates Entry into Epithelial and Endothelial Cells
J. Virol., January 1, 2008; 82(1): 60 - 70.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Microbiol.Home page
C. S. Miller, J. R. Berger, Y. Mootoor, S. A. Avdiushko, H. Zhu, and R. J. Kryscio
High prevalence of multiple human herpesviruses in saliva from human immunodeficiency virus-infected persons in the era of highly active antiretroviral therapy.
J. Clin. Microbiol., July 1, 2006; 44(7): 2409 - 2415.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
S. F. Stone, P. Price, and M. A. French
Cytomegalovirus (CMV)-specific CD8+ T cells in individuals with HIV infection: correlation with protection from CMV disease
J. Antimicrob. Chemother., April 1, 2006; 57(4): 585 - 588.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
E. P. Tchesnokov, C. Gilbert, G. Boivin, and M. Gotte
Role of Helix P of the Human Cytomegalovirus DNA Polymerase in Resistance and Hypersusceptibility to the Antiviral Drug Foscarnet
J. Virol., February 1, 2006; 80(3): 1440 - 1450.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.